Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib In Patients With Active Rheumatoid Arthritis

Pfizer Inc. PFE announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor. ORAL Standard is a completed twelve-month study in patients with moderate-to-severe active rheumatoid arthritis who had an inadequate response to methotrexate and were randomized to receive tofacitinib 5 or 10 mg BID, adalimumab 40 mg subcutaneously every other week or placebo, each of which was added to stable background MTX.